TNF-α inhibitors outperform IL-12/23 antagonists and PDE4 therapy

Key clinical point: Among biologic-naive individuals with psoriatic arthritis (PsA), interleukin-12/23 (IL-12/23) antagonists were less effective than tumor necrosis factor-alpha (TNF-α) inhibitors. PDE4 treatment was significantly less effective than TNF-α inhibitors among biologic-experienced individuals.

Major finding: Among biologic-naïve individuals, IL-12/23 was less effective than TNF-α (adjusted relative risk [aRR], 0.63; 95% confidence interval [CI], 0.45-0.89), whereas PDE4 treatment was less effective than TNF-α inhibitor among biologic-experienced individuals (aRR, 0.67; 95% CI, 0.46-0.96).

Study details: Findings are from a retrospective study of 2,730 commercially insured and Medicare Advantage beneficiaries with PsA.

,

Disclosures: The authors did not declare any specific funding for this research. GC Alexander declared being Chair of FDA’s peripheral and central nervous system advisory committee, serving as a paid advisor to IQVIA, and being a consultant and holding equity in Monument Analytics. JR Curtis declared receiving consultancies and funding from pharmaceutical companies.

Source: Zhang H et al. RMD Open. 2021 Apr 16. doi: 10.1136/rmdopen-2020-001399.